Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. 2014

M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
1] Department of Clinical Physiology and Nuclear Medicine, Bispebjerg University Hospital, Copenhagen, Denmark [2] Department of Endocrinology and Internal Medicine, Bispebjerg University Hospital, Copenhagen, Denmark [3] Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

OBJECTIVE Glucose-dependent insulinotropic polypeptide (GIP) appears to have a role in lipid metabolism. Recently, we showed that GIP in combination with hyperinsulinemia and hyperglycemia increases triglyceride uptake in abdominal, subcutaneous adipose tissue in lean humans. It has been suggested that increased GIP secretion in obesity will promote lipid deposition in adipose tissue. In light of the current attempts to employ GIP antagonists in the treatment and prevention of human obesity, the present experiments were performed in order to elucidate whether the adipose tissue lipid metabolism would be enhanced or blunted during a GIP, hyperinsulinemic and hyperglycemic (HI-HG) clamp in obese subjects with either normal glucose tolerance (NGT) or impaired glucose tolerance (IGT). METHODS Sixteen obese (BMI>30 kg m(-2)) subjects were divided into two groups, based on their plasma glucose response to an oral glucose challenge: (i) NGT and (ii) IGT. Abdominal, subcutaneous adipose tissue lipid metabolism was studied by conducting measurements of arteriovenous concentrations of metabolites and regional adipose tissue blood flow (ATBF) during GIP (1.5 pmol kg(-1) min(-1)) in combination with a HI-HG clamp. RESULTS In both groups, ATBF responses were significantly lower than what we have found previously in healthy, lean subjects (P<0.0001). The flow response was significantly lower in the IGT group than in the NGT group (P=0.03). It was not possible to show any increase in the lipid deposition in adipose tissue under the applied experimental conditions and likewise the circulating triglyceride (TAG) concentrations remained constant. CONCLUSIONS The applied GIP, HI-HG clamp did not induce any changes in TAG uptake in adipose tissue in obese subjects. This may be due to a blunted increase in ATBF. These experiments therefore suggest that GIP does not have a major role in postprandial lipid metabolism in obese subjects.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D011964 Receptors, Gastrointestinal Hormone Cell surface proteins that bind gastrointestinal hormones with high affinity and trigger intracellular changes influencing the behavior of cells. Most gastrointestinal hormones also act as neurotransmitters so these receptors are also present in the central and peripheral nervous systems. Gastrointestinal Hormone Receptors,Intestinal Hormone Receptors,Receptors, Gastrointestinal Peptides,Gastrointestinal Hormone Receptor,Intestinal Hormone Receptor,Receptors, Gastrointestinal Hormones,Receptors, Intestinal Hormone,Gastrointestinal Hormones Receptors,Gastrointestinal Peptides Receptors,Hormone Receptor, Gastrointestinal,Hormone Receptor, Intestinal,Hormone Receptors, Gastrointestinal,Hormone Receptors, Intestinal,Hormones Receptors, Gastrointestinal,Peptides Receptors, Gastrointestinal,Receptor, Gastrointestinal Hormone,Receptor, Intestinal Hormone
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005749 Gastric Inhibitory Polypeptide A gastrointestinal peptide hormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of GASTRIC ACID secretion. Glucose-Dependent Insulinotropic Peptide,Gastric-Inhibitory Polypeptide,Glucose Dependent Insulinotropic Peptide,Glucose-Dependent Insulin-Releasing Peptide,Glucose Dependent Insulin Releasing Peptide,Inhibitory Polypeptide, Gastric,Insulin-Releasing Peptide, Glucose-Dependent,Insulinotropic Peptide, Glucose-Dependent,Peptide, Glucose-Dependent Insulin-Releasing,Peptide, Glucose-Dependent Insulinotropic,Polypeptide, Gastric Inhibitory,Polypeptide, Gastric-Inhibitory
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias

Related Publications

M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
January 2019, Journal of diabetes investigation,
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
April 2024, The Journal of endocrinology,
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
October 2014, Journal of immunology (Baltimore, Md. : 1950),
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
December 2011, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
December 2004, Best practice & research. Clinical endocrinology & metabolism,
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
November 2013, Obesity (Silver Spring, Md.),
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
December 2011, Danish medical bulletin,
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
July 2004, Diabetes care,
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
December 1985, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Asmar, and L Simonsen, and N Arngrim, and J J Holst, and F Dela, and J Bülow
February 2009, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!